TELA

TELA has a genuine commercial story: revenue compounded from $29.5M (FY2021) to $80.3M (FY2025), grew +15.8% last year, and carries a healthy 67.7% gross margin on its OviTex soft-tissue matrices in a large hernia/reconstruction market. At a $32.3M market cap and 0.4x P/S, the top line alone looks cheap. That is the entire bull case — and it is not enough.

The problem is that revenue growth is not converting into operating leverage, and the balance sheet is stressed to the point of fragility. Operating loss was -$33.8M, essentially flat YoY (+1.1%), and the net loss actually widened to -$38.8M from -$37.8M despite 16% more revenue. Five straight years of $33–47M losses have produced a -$398M accumulated deficit and left stockholders' equity at just $6.31M, down 77.8% in one year, against $75.1M of liabilities — an 11.9x liabilities/equity ratio. The equity is a thin sliver sitting on top of $60.0M of Perceptive credit-facility debt maturing November 2030, with covenants that limit financing flexibility and, if breached, let the lender accelerate and foreclose on collateral.